1. From the Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group and University of California-San Francisco/Mount Zion Cancer Center, University of California-San Francisco, San Francisco, California, and TAP Pharmaceutical Products, Inc., Lake Forest, Illinois